231 related articles for article (PubMed ID: 34286913)
21. The TiHoCL panel for canine lymphoma: a feasibility study integrating functional genomics and network biology approaches for comparative oncology targeted NGS panel design.
Fibi-Smetana S; Inglis C; Schuster D; Eberle N; Granados-Soler JL; Liu W; Krohn S; Junghanss C; Nolte I; Taher L; Murua Escobar H
Front Vet Sci; 2023; 10():1301536. PubMed ID: 38144469
[TBL] [Abstract][Full Text] [Related]
22. Comprehensive routine diagnostic screening to identify predictive mutations, gene amplifications, and microsatellite instability in FFPE tumor material.
Steeghs EMP; Kroeze LI; Tops BBJ; van Kempen LC; Ter Elst A; Kastner-van Raaij AWM; Hendriks-Cornelissen SJB; Hermsen MJW; Jansen EAM; Nederlof PM; Schuuring E; Ligtenberg MJL; Eijkelenboom A
BMC Cancer; 2020 Apr; 20(1):291. PubMed ID: 32264863
[TBL] [Abstract][Full Text] [Related]
23. Comprehensive assay for the molecular profiling of cancer by target enrichment from formalin-fixed paraffin-embedded specimens.
Kohsaka S; Tatsuno K; Ueno T; Nagano M; Shinozaki-Ushiku A; Ushiku T; Takai D; Ikegami M; Kobayashi H; Kage H; Ando M; Hata K; Ueda H; Yamamoto S; Kojima S; Oseto K; Akaike K; Suehara Y; Hayashi T; Saito T; Takahashi F; Takahashi K; Takamochi K; Suzuki K; Nagayama S; Oda Y; Mimori K; Ishihara S; Yatomi Y; Nagase T; Nakajima J; Tanaka S; Fukayama M; Oda K; Nangaku M; Miyazono K; Miyagawa K; Aburatani H; Mano H
Cancer Sci; 2019 Apr; 110(4):1464-1479. PubMed ID: 30737998
[TBL] [Abstract][Full Text] [Related]
24. Next generation sequencing in cancer: opportunities and challenges for precision cancer medicine.
Paolillo C; Londin E; Fortina P
Scand J Clin Lab Invest Suppl; 2016; 245():S84-91. PubMed ID: 27542004
[TBL] [Abstract][Full Text] [Related]
25. Assessment of Capture and Amplicon-Based Approaches for the Development of a Targeted Next-Generation Sequencing Pipeline to Personalize Lymphoma Management.
Hung SS; Meissner B; Chavez EA; Ben-Neriah S; Ennishi D; Jones MR; Shulha HP; Chan FC; Boyle M; Kridel R; Gascoyne RD; Mungall AJ; Marra MA; Scott DW; Connors JM; Steidl C
J Mol Diagn; 2018 Mar; 20(2):203-214. PubMed ID: 29429887
[TBL] [Abstract][Full Text] [Related]
26. Implementation of next generation sequencing technology for somatic mutation detection in routine laboratory practice.
Giardina T; Robinson C; Grieu-Iacopetta F; Millward M; Iacopetta B; Spagnolo D; Amanuel B
Pathology; 2018 Jun; 50(4):389-401. PubMed ID: 29752127
[TBL] [Abstract][Full Text] [Related]
27. New molecular targets in canine hemangiosarcoma-Comparative review and future of the precision medicine.
Kapturska KM; Pawlak A
Vet Comp Oncol; 2023 Sep; 21(3):357-377. PubMed ID: 37308243
[TBL] [Abstract][Full Text] [Related]
28. Next-generation sequencing in precision oncology: challenges and opportunities.
Kruglyak KM; Lin E; Ong FS
Expert Rev Mol Diagn; 2014 Jul; 14(6):635-7. PubMed ID: 24791810
[TBL] [Abstract][Full Text] [Related]
29. Sensitivity of next-generation sequencing assays detecting oncogenic fusions in plasma cell-free DNA.
Supplee JG; Milan MSD; Lim LP; Potts KT; Sholl LM; Oxnard GR; Paweletz CP
Lung Cancer; 2019 Aug; 134():96-99. PubMed ID: 31320002
[TBL] [Abstract][Full Text] [Related]
30. Applications of next-generation sequencing in hematologic malignancies.
Ramkissoon LA; Montgomery ND
Hum Immunol; 2021 Nov; 82(11):859-870. PubMed ID: 33648805
[TBL] [Abstract][Full Text] [Related]
31. Validation of a next-generation sequencing assay for clinical molecular oncology.
Cottrell CE; Al-Kateb H; Bredemeyer AJ; Duncavage EJ; Spencer DH; Abel HJ; Lockwood CM; Hagemann IS; O'Guin SM; Burcea LC; Sawyer CS; Oschwald DM; Stratman JL; Sher DA; Johnson MR; Brown JT; Cliften PF; George B; McIntosh LD; Shrivastava S; Nguyen TT; Payton JE; Watson MA; Crosby SD; Head RD; Mitra RD; Nagarajan R; Kulkarni S; Seibert K; Virgin HW; Milbrandt J; Pfeifer JD
J Mol Diagn; 2014 Jan; 16(1):89-105. PubMed ID: 24211365
[TBL] [Abstract][Full Text] [Related]
32. Personalised medicine in veterinary oncology: one to cure just one.
Klopfleisch R
Vet J; 2015 Aug; 205(2):128-35. PubMed ID: 25641551
[TBL] [Abstract][Full Text] [Related]
33. Application of next-generation sequencing in clinical oncology to advance personalized treatment of cancer.
Guan YF; Li GR; Wang RJ; Yi YT; Yang L; Jiang D; Zhang XP; Peng Y
Chin J Cancer; 2012 Oct; 31(10):463-70. PubMed ID: 22980418
[TBL] [Abstract][Full Text] [Related]
34. How Genetics and Genomics Advances Are Rewriting Pediatric Cancer Research and Clinical Care.
Cipri S; Abenavoli L; Boccuto L; Del Baldo G; Mastronuzzi A
Medicina (Kaunas); 2022 Oct; 58(10):. PubMed ID: 36295546
[TBL] [Abstract][Full Text] [Related]
35. Leveraging the Fragment Length of Circulating Tumour DNA to Improve Molecular Profiling of Solid Tumour Malignancies with Next-Generation Sequencing: A Pathway to Advanced Non-invasive Diagnostics in Precision Oncology?
Underhill HR
Mol Diagn Ther; 2021 Jul; 25(4):389-408. PubMed ID: 34018157
[TBL] [Abstract][Full Text] [Related]
36. Circulating Tumor DNA Mutation Profiling by Targeted Next Generation Sequencing Provides Guidance for Personalized Treatments in Multiple Cancer Types.
Shu Y; Wu X; Tong X; Wang X; Chang Z; Mao Y; Chen X; Sun J; Wang Z; Hong Z; Zhu L; Zhu C; Chen J; Liang Y; Shao H; Shao YW
Sci Rep; 2017 Apr; 7(1):583. PubMed ID: 28373672
[TBL] [Abstract][Full Text] [Related]
37. Next generation sequencing of vitreoretinal lymphomas from small-volume intraocular liquid biopsies: new routes to targeted therapies.
Cani AK; Hovelson DH; Demirci H; Johnson MW; Tomlins SA; Rao RC
Oncotarget; 2017 Jan; 8(5):7989-7998. PubMed ID: 28002793
[TBL] [Abstract][Full Text] [Related]
38. Next generation MUT-MAP, a high-sensitivity high-throughput microfluidics chip-based mutation analysis panel.
Schleifman EB; Tam R; Patel R; Tsan A; Sumiyoshi T; Fu L; Desai R; Schoenbrunner N; Myers TW; Bauer K; Smith E; Raja R
PLoS One; 2014; 9(3):e90761. PubMed ID: 24658394
[TBL] [Abstract][Full Text] [Related]
39. [Lung cancer molecular testing, what role for Next Generation Sequencing and circulating tumor DNA].
Pécuchet N; Legras A; Laurent-Puig P; Blons H
Ann Pathol; 2016 Jan; 36(1):80-93. PubMed ID: 26803564
[TBL] [Abstract][Full Text] [Related]
40. Amplicon-Based NGS Panels for Actionable Cancer Target Identification in Follicular Cell-Derived Thyroid Neoplasia.
Madsen MB; Kiss K; Cilius Nielsen F; Bennedbæk FN; Rossing M
Front Endocrinol (Lausanne); 2020; 11():146. PubMed ID: 32265839
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
